Compare Merck & Co., Inc. (MRK) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Rivian Automotive, Inc. — how do they compare? Merck & Co., Inc. trades at $144.69 (market cap $351.28B), while Rivian Automotive, Inc. trades at $14.21 (market cap $20.75B). The key difference: Merck & Co., Inc. is far larger — about 16.9× Rivian Automotive, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Rivian Automotive, Inc. for 61 Days on average.
| MRK | RIVN | |
|---|---|---|
Market Cap | $351.28B | $20.75B |
Volume | 7,969,665 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $22.45 |
52-Week Low | $82.49 | $12.50 |
Typical Hold Time | 98 Days | 61 Days |
Enterprise Value | $398.04B | $20.79B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Rivian Automotive (RIVN) trades at $14.34, down 1.17% amid bearish technical signals despite strong Q3 2026 delivery growth of 46% to 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving cash flow trends with operating losses narrowing from -$5.1B in 2022 to -$779M in 2025. Recent news highlights R2 SUV production ramp and autonomy technology development, though the stock faces pressure from unchanged 2026 guidance and a recent R2 battery pack recall.
Rivian presents a high-risk growth opportunity with significant cash burn but improving operational efficiency. The path to profitability depends on successful R2 scaling and future autonomy revenue, while near-term risks include execution challenges and competitive EV market pressures. Analyst consensus remains cautiously optimistic with a $16.89 price target representing 18% upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
